Clinical Trial Update: Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating BNP7787 to prevent neurotoxicity in metastatic breast cancer patients receiving weekly paclitaxel has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Diseases
• Breast Neoplasms

Drugs mentioned

• BNP7787
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: BioNumerik Pharmaceuticals, Inc. | Conditions: Breast Neoplasms, Breast Diseases | Phase 3 | Status: COMPLETED